FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors


Search recent Press Releases: Regeneron Pharmaceuticals Inc-related press releases
Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12015014000205/21/15 new patent  Use of a pcsk9 inhibitor to treat hyperlipidemia
22015014355805/21/15 new patent  Non-human animals having a humanized b-cell activating factor gene
32015014355905/21/15 new patent  Non-human animals having a humanized a proliferation-inducing ligand gene
42015014356105/21/15 new patent  Non-human animals having a humanized b-cell activating factor gene
52015014356205/21/15 new patent  Non-human animals having a humanized a proliferation-inducing ligand gene
62015011955604/30/15Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
72015011075404/23/15High resolution allele identification
82015011080104/23/15Human antibodies to gfr alpha 3 and methods of use thereof
92015010573504/16/15Syringe pistons, systems and methods
102015010696104/16/15Humanized il-15 animals
112015009929604/09/15Promoter-regulated differentiation-dependent self-deleting cassette
122015010003004/09/15Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
132015008967803/26/15Non-human animals having a humanized signal-regulatory protein gene
142015008967903/26/15Non-human animals having a humanized signal-regulatory protein gene
152015008968003/26/15Human lambda light chain mice
162015007908703/19/15Vegf antagonist formulations
172015008246903/19/15Humanized il-7 rodents
182015006418903/05/15Method of treating cancer with dll4 antagonist and chemotherapeutic agent
192015006790103/05/15Production of fertile xy female animals from xy es cells
202015005622102/26/15Anti-prlr antibodies and uses thereof
212015005622202/26/15Anti-prlr antibodies and uses thereof
222015005900902/26/15Methods for making fully human bispecific antibodies using a common light chain
232015004706102/12/15Humanized m-csf mice
242015004706202/12/15Lincrna-deficient non-human animals
252015003733902/05/15Anti-activin a antibodies and uses thereof
262015004025302/05/15Genetically modified major histocompatibility complex mice
272015002441201/22/15Humanized fcgammar mice
282015001717601/15/15Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
292015001718201/15/15Methods for treating nasal polyposis by administering an il-4r antagonist
302015002022401/15/15Non-human animals with modified immunoglobulin heavy chain sequences
312015001056801/08/15Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
322015001302201/08/15Humanized il-6 and il-6 receptor
332015001302301/08/15Humanized il-6 and il-6 receptor
342014035637012/04/14Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
352014035637112/04/14Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
362014035637212/04/14Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
372014033134011/06/14Methods and compositions for generating a mouse
382014032221510/30/14Methods of inhibiting tumor growth by antagonizing il-6 receptor
392014031524910/23/14Inducible eukaryotic expression system
402014028987609/25/14Mice that make heavy chain antibodies
412014027164209/18/14Il-33 antagonists and uses thereof
422014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
432014027165809/18/14Anti-il-33 antibodies and uses thereof
442014027168109/18/14High affinity human antibodies to human il-4 receptor
452014027309509/18/14Serum-free cell culture medium
462014027548909/18/14Apelin fusion proteins and uses thereof
472014028315809/18/14Rodents with conditional acvr1 mutant alleles
482014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
492014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
502014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
512014025599509/11/14High affinity antibodies to human il-6 receptor
522014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
532014024350408/28/14Antibodies comprising chimeric constant domains
542014024546608/28/14Humanized t cell co-receptor mice
552014024546708/28/14Genetically modified major histocompatibility complex mice
562014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
572014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
582014021377307/31/14Adam6 mice
592014019655007/17/14Systems and devices for sample handling
602014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
612014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
622014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
632014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
642014017887906/26/14Compositions and methods for modifying cells
652014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
662014015470106/05/14Humanized fc gamma r mice
672014015568906/05/14Methods of modifying genes in eukaryotic cells
682014015744506/05/14Low affinity fcgr deficient mice
692014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
702014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
712014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
722014013471905/15/14Recombinant cell surface capture proteins
732014013727505/15/14Hybrid light chain mice
742014013019305/08/14Mice that make vl binding proteins
752014013019405/08/14Mice that make vl binding proteins
762014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
772014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
782014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
792014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
802014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
812014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
822014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
832014007297903/13/14Isolating cells expressing secreted proteins
842014007298003/13/14Isolating cells expressing secreted proteins
852014007301003/13/14Methods of modifying eukaryotic cells
862014007558603/13/14Parental cell lines for making cassette-free f1 progeny
872014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
882014005690702/27/14Anti-asic1 antibodies and uses thereof
892014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
902014004106802/06/14Methods of modifying eukaryotic cells
912014003333601/30/14Methods of modifying eukaryotic cells
922014003333701/30/14Methods of modifying eukaryotic cells
932014002363701/23/14Methods of modifying eukaryotic cells
942014001722801/16/14Humanized light chain mice
952014001722901/16/14Methods of modifying eukaryotic cells
962014001723801/16/14Methods of modifying eukaryotic cells
972014001769501/16/14Isolating cells expressing secreted proteins
982014001778101/16/14Methods of modifying eukaryotic cells
992014001778201/16/14Methods for modifying eukaryotic cells
1002014001852201/16/14Methods of modifying eukaryotic cells
1012014002012401/16/14Methods of modifying eukaryotic cells
1022014002012501/16/14Methods of modifying eukaryotic cells
1032014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1042014001345701/09/14Methods of modifying eukaryotic cells
1052013034453812/26/13Human antibodies to the glucagon receptor
1062013034010412/19/13Humanized il-7 rodents
1072013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
1082013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
1092013032326112/05/13Purified antibody composition
1102013032378812/05/13Production cell line enhancers
1112013032379012/05/13Human lambda light chain mice
1122013032379112/05/13Restricted immunoglobulin heavy chain mice
1132013032664712/05/13Human lambda light chain mice
1142013030967011/21/13Nuclease-mediated targeting with large targeting vectors
1152013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
1162013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
1172013029509711/07/13Human antibodies to fel d1 and methods of use thereof
1182013028075810/24/13Fusion polypeptides capable of activating receptors
1192013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
1202013026657410/10/13Human antibodies to human angiopoietin-like protein 4
1212013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
1222013025988110/03/13Fusion polypeptides capable of activating receptors
1232013026105610/03/13Vegf antagonist formulations
1242013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1252013025491109/26/13Adam6 mice
1262013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1272013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1282013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1292013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1302013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1312013023053109/05/13Human antibodies to clostridium difficile toxins
1322013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1332013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1342013020949208/15/13Anti-tie2 antibodies and uses thereof
1352013021013708/15/13Methods of modifying eukaryotic cells
1362013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1372013019587808/01/13Anti-asic1 antibodies and uses thereof
1382013019887908/01/13Humanized universal light chain mice
1392013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1402013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1412013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1422013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1432013018581907/18/13Genetically modified major histocompatibility complex animals
1442013018582007/18/13Genetically modified major histocompatibility complex animals
1452013018582107/18/13Common light chain mouse
1462013017114907/04/13Anti-angptl3 antibodies and uses thereof
1472013016478606/27/13Fucosylation-deficient cells
1482013015731306/20/13High affinity antibodies to human il-6 receptor
1492013016015306/20/13Humanized light chain mice
1502013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1512013013710105/30/13Methods of modifying eukaryotic cells
1522013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1532013012983005/23/13Polymer protein microparticles
1542013013037205/23/13Enhanced expression and stability regions
1552013013038805/23/13Methods of modifying eurakyotic cells
1562013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1572013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1582013011787305/09/13Humanized il-6 and il-6 receptor
1592013010905305/02/13Genetically modified t cell receptor mice
1602013011161605/02/13Genetically modified major histocompatibility complex mice
1612013011161705/02/13Genetically modified major histocompatibility complex mice
1622013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1632013009628704/18/13Restricted immunoglobulin heavy chain mice
1642013008429704/04/13Anti-erbb3 antibodies and uses thereof
1652013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1662013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1672013007867503/28/13High affinity human antibodies to human il-4 receptor
1682013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1692013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1702013003490202/07/13Fusion polypeptides capable of activating receptors
1712013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1722012032210812/20/12Adam6 mice
1732012032349712/20/12Non-hypergeometric overlap probability
1742012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1752012026035710/11/12Low affinity fcgr deficient mice
1762012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1772012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1782012019230007/26/12Common light chain mouse
1792012017868307/12/12Vegf antagonist formulations
1802012016468806/28/12High affinity human antibodies to human nerve growth factor
1812012013501005/31/12High affinity human antibodies to human il-4 receptor
1822012012867905/24/12Human antibodies to the glucagon receptor
1832012011464505/10/12Use of il-1 antagonists to treat pseudogout
1842012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1852012011466505/10/12Human antibodies to human rankl
1862012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1872012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1882012010103504/26/12Vegf antagonist formulations
1892012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1902012009657204/19/12Mice that make vl binding proteins
1912012008792904/12/12Vegf antagonist formulations for intravitreal administration
1922012008300004/05/12Neuropeptide release assay for sodium channels
1932012007679003/29/12Anti-cd48 antibodies and uses thereof
1942012007086103/22/12Human lambda light chain mice
1952012007300403/22/12Hybrid light chain mice
1962012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1972012005207203/01/12High affinity human antibodies to human il-4 receptor
1982012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1992012002140901/26/12Common light chain mouse
2002012001496801/19/12Stabilized formulations containing anti-ngf antibodies
2012012000369701/05/12High affinity antibodies to human il-6 receptor
2022011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
2032011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
2042011030796612/15/11Mice expressing human voltage-gated sodium channels
2052011030796812/15/11Production of fertile xy animals from xy es cells
2062011029363012/01/11Antibodies to human gdf8
2072011028337611/17/11Methods of modifying eukaryotic cells
2082011026918711/03/11High affinity human antibodies to human il-18 receptor
2092011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2102011025655610/20/11Humanized fcgr mice
2112011025658710/20/11High affinity human antibodies to human nerve growth factor
2122011025760110/20/11Vegf antagonist formulations for intravitreal administration
2132011025871010/20/11Methods of modifying eukaryotic cells
2142011019545408/11/11Common light chain mouse
2152011018917608/04/11Methods of treating diseases with dll4 antagonists
2162011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2172011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2182011016565007/07/11Fusion polypeptides capable of activating receptors
2192011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2202011015090506/23/11Human antibodies to human delta like ligand 4
2212011015451206/23/11Humanized fc gamma r mice
2222011014593706/16/11Mice that make heavy chain antibodies
2232011010479905/05/11Multifunctional alleles
2242011008168104/07/11Human antibodies to human cd20 and using thereof
2252011006590203/17/11High affinity human antibodies to pcsk9
2262011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2272011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2282011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2292011002728602/03/11High affinity human antibodies to human angiopoietin-2
2302011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2312011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2322011000837401/13/11Use of il-1 antagonists to treat gout
2332010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2342010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2352010031662712/16/10Human antibodies to human il-6 receptor
2362010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2372010030443612/02/10Fucosylation-deficient cells
2382010029110711/18/10High affinity human antibodies to human il-4 receptor
2392010029162611/18/10Enhanced expression and stability regions
2402010027993311/04/10Vegf antagonist formulations
2412010023380309/16/10Fusion polypeptides capable of activating receptors
2422010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2432010016676807/01/10High affinity human antibodies to pcsk9
2442010012981705/27/10Identifying germline competent embryonic stem cells
2452010011192105/06/10Use of il-1 antagonists to treat gout
2462010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2472010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2482010004725402/25/10High affinity human antibodies to human il-4 receptor
2492010004233002/18/10Non-hypergeometric overlap probability



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE